Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.59 |
| ▸ | FES | P07332 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31321081 | 1.00 | MAPT (0.69) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 | |
| Benzenemethanethiol SCHEMBL11032049 | 0.90 | CYP3A4 (0.63) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 | |
| SCHEMBL2433131 | 0.87 | MAPT (0.75) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 | |
| SCHEMBL16610098 | 0.86 | MAPT (0.84) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 | |
| SCHEMBL6164416 | 0.85 | MAPT (0.71) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 | |
| SCHEMBL19632801 | 0.84 | MAPT (0.81) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 | |
| SCHEMBL934604 | 0.84 | EPHX2 (0.63) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 | |
| SCHEMBL12313357 | 0.84 | HDAC2 (0.56) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 | |
| SCHEMBL14743049 | 0.84 | MAPT (0.66) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 | |
| SCHEMBL8288445 | 0.83 | MAPT (0.69) | MAPTCYP3A4KMT2ACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915354-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018461-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | claimed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021018012-A1 | IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | 珠海宇繁生物科技有限责任公司 | 2021-02-04 | — | — | WO | disclosed |
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-01-07 | — | — | US | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-7629467-B2 | 5-lipoxygenase activating protein inhibitors; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1630165-A1 | [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | VCAM1, ICAM1, CD69 | MAPT 3264/4885CYP3A4 921/4885KMT2A 2594/4885 |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | MAPT 4307/4885CYP3A4 1704/4885KMT2A 2048/4885 |
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | MAPT 3454/4885CYP3A4 4644/4885KMT2A 1750/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | MAPT 3454/4885CYP3A4 4644/4885KMT2A 1750/4885 |
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | MAPT 929/4885CYP3A4 115/4885KMT2A 2145/4885 |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | MAPT 3454/4885CYP3A4 4644/4885KMT2A 1750/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | MAPT 333/4885CYP3A4 2183/4885KMT2A 3245/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | MAPT 3454/4885CYP3A4 4644/4885KMT2A 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.